ARUP Laboratories has launched the clinical CLARISPECT Multiple Myeloma MRD by Spectral Flow Cytometry assay for multiple ...

ARUP Laboratories today announced the launch of ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new assay will characterize small neoplastic populations with greater confidence ...

Jul 22, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted the ...

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB ...

A fading hormone may unlock clues to aging and cancer defenses, but scientists warn the breakthrough comes with major ...

NeoGenomics pay s $9.8 million to settle allegations it offered discounted services to secure patient referrals.

Under the agreement, bioAffinity’s sputum analysis will be combined with Pictor’s proteomic platform to analyse inflammation.

NeoGenomics Laboratories Inc., headquartered in Florida, will pay $9,813,260 to settle allegations that it provided ...

Life sciences companies continue to operate in an environment supported by growing investment in biomedical research, ...

Claire Boyte-White is the lead writer for NapkinFinance.com, co-author of I Am Net Worthy, and an Investopedia contributor. Claire's expertise lies in corporate finance & accounting, mutual funds, ...

The tests will help identify the inflammatory pathways involved in patients with COPD and asthma to help better guide therapy selection.

Fort Myers-based NeoGenomics Laboratories agreed to pay nearly $9.8 million to settle federal allegations that it used improper compensation arrangements to generate referrals for laboratory testing ...